by MASA | Feb 28, 2026 | PANS/PANDAS, Rare Diseases
Frequently asked questions about PANS/PANDAS are here! If you want to learn more about what is PANS/PANDAS, follow this link. Q1: What are the typical symptoms? Symptoms appear suddenly and may include: Obsessive-compulsive behaviors (OCD) Severe anxiety or emotional...
by MASA | Mar 28, 2025 | Alpha-One Anti-Trypsin Deficiency, Rare Diseases
How rare is an alpha-1 antitrypsin deficiency? This disease only reportedly affects roughly 0.03% – 0.06% of individuals. Is there a cure for alpha-1 antitrypsin deficiency? Currently, there is no known cure for this rare disorder, but there are treatment...
by MASA | Mar 10, 2025 | Immunodeficiency Hypogammaglobulinemia, News, Rare Diseases
Deadline: March 21, 2025 Download CIIC Patient Scholarship Application 2025 : You can submit your application to your provider. CIIC Annual Patient Scholarship: Empowering PIDD and Rare Disease Patients The CIIC (Coalition of Immunology and Allergy Clinics) is proud...
by MASA | Aug 15, 2024 | Drug Updates, Rare Diseases
What is D.R.E.S.S.? Drug Reaction with Eosinophilia and Systemic Symptoms (D.R.E.S.S.) is a type of drug allergy which can occur as a reaction to a large variety of medications. Symptoms include fever, rash, facial swelling, enlarged lymph nodes and kidney or liver...
by MASA | Jan 31, 2024 | Immunodeficiency Hypogammaglobulinemia, Rare Diseases
What is PIDD? What is PIDD? PIDD stands for Primary Immunodeficiency Diseases. These diseases are a group of more than 500 rare, chronic disorders in which part of the body’s immune system is missing or functions improperly. Because the immune system is...
by MASA | Jan 19, 2024 | Immune System, Immunodeficiency Hypogammaglobulinemia, News, Patient Opportunity, Rare Diseases
CIIC Annual Patient Scholarship: Empowering PIDD and Rare Disease Patients The CIIC (Coalition of Immunology and Allergy Clinics) is proud to announce the continuation of its Annual Patient Scholarship program, initiated in 2021. This unique scholarship is...
